Use of dexamethasone in the management of phlebitis caused by intravenous administration of vinorelbine (navelbine)

Medical Science Research

Volumn 26, Issue 6, 1998, Pages 397-398

  Ginopoulos, Panagiotis ^a,b   Mastronikolis, Nicholas S ^a   Karana, Afroditi ^a   Papadas, Theodores ^a   Karvelas, Fotis ^a   Rathosis, Spiros ^a   Charokopos, Nicholas ^a   Mastorakou, Anna N ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Chemotherapy; Dexamethasone; Phlebitis; Vinorelbine

Indexed keywords

DEXAMETHASONE; NAVELBINE; ONDANSETRON;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DRUG INFUSION; DRUG POTENTIATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; PHLEBITIS; QUALITY OF LIFE; VOMITING;

VINCA;

EID: 0031875612     PISSN: 02698951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Depierre A, Lemalrie E, Debuois G, Garnier G, Jacoulet P, Dalphin JC. Efficacy of navelbine (NVB) in non small cell lung cancer (NSCLC). Semin Oncot 1989; 16 (Suppl 4):26-29.
2. George MJ, Heron JF, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, el al. Navelbine in advanced ovarian epithelial cancer: A study of the French oncology centers. Semin Oncol 1989; 16 (Suppl 4):30-32.
3. Fumoleau P, Delozier T, Extra JM. Cannobio L, Delgado FM, Hurtelup P. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol 1995; 22 (Suppl 5):22-29.
4. Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, el al. Vinorelbine, cisplatin and 5-FU as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicentre study. Cancer 1997; 79:1394-1400.
5. Crawford J. Update: Vinorelbine (navelbine) in non-small cell lung cancer. Semin Oncol 1996; 23 (suppl S):2-7.
6. Lacava JA, Leone BA, Machiavelli M, Romero AO, Ferez JE, Elem YL, el al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997; 15:604-609.
7. Gros S, Wright M, Morimolo M, Lataste H, Couzinier JP, Krikorian A. Experimental antilumor activity of navelbine. Semin Oncol 1989; 16 (suppl 4): 15-20.
8. Nelson RL. Dyke RW, Root MA. Comparative pharmakokinetics of vindesine. vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980:7:17-24.
9. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JO, Meininger V. In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989: 16 (suppl 4):5-8.
10. Cvitkovicz E, Izzo J. The current and future place of Vinorelbine in cancer therapy. Drugs 1992; 44 (suppl 4): 36-45.
11. Kornek GV, Halder K, Kwasny W, Hejna M, Raderer M, Meghdadi S, et al. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C, plus human granolocyte colony-stimulating factor. Br J Cancer 1996; 74:1668-1673.
12. Testolin A, Recher G, Cristoferi V, Gasparini G. Vinorelbine in pretreatment of advanced head and neck squamous cell carcinoma: A phase II study. Invest New Drugs 1994; 12:231-234.
13. Fabi A, Tonachella R, Savarese A, Cirulli S, Tomao S, Conte E, et al. A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol 1995; 6:187-189.
14. Vallejo C, Romero A, Perez J, Cuevas M, Lacava J, Sabatini C, et al. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. Am J Clin Oncol 1996; 19:584-588.
15. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12:336-341.